Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #8 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited (this stock) | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 8,100 | 552 | 436 | ₹ |
| March 31, 2026 | 7,546 | 195 | 221 | ₹ |
| Dec. 31, 2025 | 8,753 | 1,541 | 1,190 | ₹ |
| Sept. 30, 2025 | 8,828 | 1,738 | 1,337 | ₹ |
| June 30, 2025 | 8,572 | 1,905 | 1,410 | ₹ |
| March 31, 2025 | 8,528 | 2,000 | 1,587 | ₹ |
| Dec. 31, 2024 | 8,381 | 1,870 | 1,404 | ₹ |
| Sept. 30, 2024 | 8,038 | 1,911 | 1,342 | ₹ |
| June 30, 2024 | 7,696 | 1,877 | 1,392 | ₹ |
| March 31, 2024 | 7,114 | 1,602 | 1,310 | ₹ |
| Dec. 31, 2023 | 7,237 | 1,826 | 1,381 | ₹ |
| Sept. 30, 2023 | 6,903 | 1,912 | 1,482 | ₹ |
| June 30, 2023 | 6,758 | 1,846 | 1,405 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 33,700 | 5,379 | 4,158 |
| March 31, 2025 | 32,644 | 7,658 | 5,725 |
| March 31, 2024 | 28,011 | 7,186 | 5,578 |
| March 31, 2023 | 24,670 | 6,012 | 4,507 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 5,674 | -6,549 | 829 | 2,331 | 3,343 |
| March 31, 2025 | 4,643 | -5,102 | 1,186 | 2,750 | 1,892 |
| March 31, 2024 | 4,543 | -4,028 | -376 | 1,640 | 2,903 |
| March 31, 2023 | 5,887 | -4,137 | -2,686 | 1,132 | 4,755 |
| March 31, 2022 | 2,811 | -2,639 | -242 | 1,466 | 1,345 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 58,123 | 38,231 | 37,808 | 6,294 | 0 | 30,179 | 16,747 | 1,537 | 10,078 | 7,653 |
| March 31, 2025 | 49,427 | 33,927 | 33,466 | 3,804 | 380 | 25,018 | 13,034 | 1,465 | 7,298 | 7,108 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
